The global burden of SLE: prevalence, health disparities and socioeconomic impact

EE Carter, SG Barr, AE Clarke - Nature reviews rheumatology, 2016 - nature.com
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that can
potentially lead to serious organ complications and even death. Its global burden—in terms …

Systematic review of the epidemiology of systemic lupus erythematosus in the Asia‐Pacific region: prevalence, incidence, clinical features, and mortality

RW Jakes, SC Bae, W Louthrenoo… - Arthritis care & …, 2012 - Wiley Online Library
Objective Systemic lupus erythematosus (SLE), a chronic multisystem autoimmune disease
with a wide spectrum of manifestations, shows considerable variation across the globe …

A phase III, randomized, placebo‐controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus …

R Furie, M Petri, O Zamani, R Cervera… - Arthritis & …, 2011 - Wiley Online Library
Objective To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab
plus standard therapy compared with placebo plus standard therapy in active systemic lupus …

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

SV Navarra, RM Guzmán, AE Gallacher, S Hall… - The Lancet, 2011 - thelancet.com
Background Systemic lupus erythematosus is a heterogeneous autoimmune disease that is
associated with B-cell hyperactivity, autoantibodies, and increased concentrations of B …

N‐acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double …

ZW Lai, R Hanczko, E Bonilla, TN Caza… - Arthritis & …, 2012 - Wiley Online Library
Objective Systemic lupus erythematosus (SLE) patients exhibit T cell dysfunction, which can
be regulated through mitochondrial transmembrane potential (Δψm) and mammalian target …

Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus

R Furie, EF Morand, AD Askanase, EM Vital… - Lupus, 2021 - journals.sagepub.com
Background Systemic lupus erythematosus (SLE) management objectives include
preventing disease flares while minimizing glucocorticoid exposure. Pooled data from the …

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials

MA Petri, RF Van Vollenhoven, J Buyon… - Arthritis & …, 2013 - Wiley Online Library
Objective To identify predictors of moderate‐to‐severe systemic lupus erythematosus (SLE)
flare in 562 patients treated with standard therapy alone in phase III belimumab trials, and to …

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort

MF Ugarte-Gil, E Acevedo-Vásquez… - Annals of the …, 2015 - ard.bmj.com
Purpose To determine the association between the number of flares systemic lupus
erythematosus (SLE) patients experience and damage accrual, independently of other …

Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan

C Garris, P Jhingran, D Bass… - Journal of medical …, 2013 - Taylor & Francis
Objective: To assess healthcare resource utilization and costs in a cohort of US managed
care patients with systemic lupus erythematosus (SLE). Methods: Claims data from a large …

Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review

N Gensous, A Marti, T Barnetche, P Blanco… - Arthritis research & …, 2017 - Springer
Background The aim of this study was to identify the most reliable biomarkers in the
literature that could be used as flare predictors in systemic lupus erythematosus (SLE) …